File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Potential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study

TitlePotential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study
Authors
Keywordsvenous thromboembolism
orthopedic surgery
tourniquet
body mass index
rivaroxaban thromboprophylaxis
Issue Date2020
PublisherSage Publications, Inc. The Journal's web site is located at http://cat.sagepub.com
Citation
Clinical and Applied Thrombosis/Hemostasis, 2020, Epub 2020-10-16, v. 26 How to Cite?
AbstractRivaroxaban after total knee arthroplasty (TKA) is used to prevent postoperative venous thromboembolism (VTE); however, despite thromboprophylaxis, some patients still develop postoperative VTE. To determine whether tourniquet time, time to initiate rivaroxaban (TTIRIV), or Body Mass Index (BMI) was associated with postoperative VTE. A retrospective case-control study was conducted. Those patients that developed VTE despite prophylaxis (cases) were compared to controls (no VTE). A univariate analysis was conducted (p < 0.05 statistically significant). Seven VTE cases were identified from 234 TKA-patients. Patients with and without VTE had BMI of 40.1+ 9.1 and 32.8 + 7.5, respectively (p = 0.064). TTIRIV in VTE and control group was 28.2+4.7 hours and 26.4+4.2 hours, respectively (p = 0.39). Mean tourniquet time in VTE and control group was 65.0+ 8.7 minutes and 49 + 8.8 minutes, respectively (p = 0.0007). Statistically significant differences in tourniquet times were noted between VTE and non-VTE group but not for TTIRIV and BMI. Prolonged tourniquet use could pose a potential risk factor for postoperative VTE. Thromboprophylaxis management may need to be adjusted, based on patient-specific factors that could include increasing doses of oral anticoagulants and/or mechanical prophylaxis. However, further large-scale studies are required to establish pathophysiology.
Persistent Identifierhttp://hdl.handle.net/10722/290525
ISSN
2023 Impact Factor: 2.3
2023 SCImago Journal Rankings: 0.633
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorMian, O-
dc.contributor.authorMatino, D-
dc.contributor.authorRoberts, R-
dc.contributor.authorMcDonald, E-
dc.contributor.authorChan, AKC-
dc.contributor.authorChan, HHW-
dc.date.accessioned2020-11-02T05:43:29Z-
dc.date.available2020-11-02T05:43:29Z-
dc.date.issued2020-
dc.identifier.citationClinical and Applied Thrombosis/Hemostasis, 2020, Epub 2020-10-16, v. 26-
dc.identifier.issn1076-0296-
dc.identifier.urihttp://hdl.handle.net/10722/290525-
dc.description.abstractRivaroxaban after total knee arthroplasty (TKA) is used to prevent postoperative venous thromboembolism (VTE); however, despite thromboprophylaxis, some patients still develop postoperative VTE. To determine whether tourniquet time, time to initiate rivaroxaban (TTIRIV), or Body Mass Index (BMI) was associated with postoperative VTE. A retrospective case-control study was conducted. Those patients that developed VTE despite prophylaxis (cases) were compared to controls (no VTE). A univariate analysis was conducted (p < 0.05 statistically significant). Seven VTE cases were identified from 234 TKA-patients. Patients with and without VTE had BMI of 40.1+ 9.1 and 32.8 + 7.5, respectively (p = 0.064). TTIRIV in VTE and control group was 28.2+4.7 hours and 26.4+4.2 hours, respectively (p = 0.39). Mean tourniquet time in VTE and control group was 65.0+ 8.7 minutes and 49 + 8.8 minutes, respectively (p = 0.0007). Statistically significant differences in tourniquet times were noted between VTE and non-VTE group but not for TTIRIV and BMI. Prolonged tourniquet use could pose a potential risk factor for postoperative VTE. Thromboprophylaxis management may need to be adjusted, based on patient-specific factors that could include increasing doses of oral anticoagulants and/or mechanical prophylaxis. However, further large-scale studies are required to establish pathophysiology.-
dc.languageeng-
dc.publisherSage Publications, Inc. The Journal's web site is located at http://cat.sagepub.com-
dc.relation.ispartofClinical and Applied Thrombosis/Hemostasis-
dc.rightsAuthor(s), Contribution Title, Journal Title (Clinical and Applied Thrombosis/Hemostasis, 2020, Epub 2020-10-16, v. 26) pp. xx-xx. Copyright © [2020] (Copyright Holder). DOI: [10.1177/1076029620962226].-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.subjectvenous thromboembolism-
dc.subjectorthopedic surgery-
dc.subjecttourniquet-
dc.subjectbody mass index-
dc.subjectrivaroxaban thromboprophylaxis-
dc.titlePotential Risk Factors Contributing to Development of Venous Thromboembolism for Total Knee Replacements Patients Prophylaxed With Rivaroxaban: A Retrospective Case-Control Study-
dc.typeArticle-
dc.identifier.emailChan, HHW: hwhoward@hku.hk-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1177/1076029620962226-
dc.identifier.pmid33064561-
dc.identifier.pmcidPMC7573710-
dc.identifier.scopuseid_2-s2.0-85092786658-
dc.identifier.hkuros318045-
dc.identifier.volumeEpub 2020-10-16, v. 26-
dc.identifier.spage1-
dc.identifier.epage8-
dc.identifier.isiWOS:000582166600001-
dc.publisher.placeUnited States-
dc.identifier.issnl1076-0296-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats